You are here
Treprostinil Data for Pulmonary Hypertension Presented at Heart, Lung Meeting
"We are very pleased to see ever-longer periods of satisfactory experience with Remodulin," said Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics. "We gain much inspiration from the knowledge that Remodulin is proving so helpful to clinicians in treating their patients with pulmonary arterial hypertension."
Remodulin received United States Food and Drug Administration approval on May 21, 2002 for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.